SOUTH SAN FRANCISCO, Calif., April 25, 2024 Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo a
Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.
Vistagen , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system disorders,. | June 13, 2023
Vistagen a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders,. | June 6, 2023